MedPath

Evidence Based QUality Improvement for Prescribing Stewardship in ICU (EQUIPS-ICU)

Not yet recruiting
Conditions
Antimicrobial Stewardship
Registration Number
NCT06666738
Lead Sponsor
University of Oxford
Brief Summary

The goal of this observational study is to learn about the implementation of a process to review antimicrobial prescriptions for adult patients in Intensive Care Unit (ICU).

The main question it aims to answer is: can a structured antimicrobial review can be implemented in ICUs?

Implementation will be supported by the use of local protocols, audit and feedback, and education. It will be evaluated by daily data collection of clinical processes and interviews with local champions.

Resources to conduct the study are provided by the Wellcome Flagship Innovations award. ("Collaboration for Research, Implementation and Training in Critical Care in Asia and Africa", reference 224048/Z/21/Z).

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
6300
Inclusion Criteria
  • All adult ICUs within CCAA-affiliated Care Quality Registries
  • ICUs must appoint a named Champion to facilitate implementation
  • All antimicrobial prescriptions for adult patients within the ICUs described above
Exclusion Criteria

• ICU's which demonstrate adoption and reach of 80% or greater (median over 2 months) of a pre-existing structured antimicrobial review

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
FidelityEvaluated over calendar month periods during months 4-6 (i.e. the three months immediately following implementation)

The proportion of prescriptions reviewed as intended (reviewed within 48hours with documentation of all 4 review components: indication, route, duration, stop date). Reported as a proportion of the number of possible reviews.

ReachEvaluated over calendar month periods during months 4-6 (i.e. the three months immediately following implementation)

Proportion of eligible patients who receive a review

AdoptionEvaluated over the calendar month period of month 7

Proportion of prescriptions reviewed as intended once implementation support has been withdrawn

Secondary Outcome Measures
NameTimeMethod
Antimicrobial Density (AD)Evaluated over calendar month periods during months 1-7 of the study.

Defined Daily Dose / 1000 patient-days. This measure of antimicrobial consumption will compare prescribed daily doses of antimicrobials to those specified by the World Health Organization (WHO) (Anatomical Therapeutic Classification (ATC) J01 Defined Daily Doses). To correct for ICU unit size the investigators will standardise by number of admitted patient-days during that month in that ICU.

Duration of TherapyEvaluated over calendar month periods during months 1-7 of the study

Number of Days of antimicrobial Therapy / 1000 patient-days Analysed at the ICU level

Antimicrobial Redundancy RateEvaluated over calendar month periods during months 1-7 of the study

Days of Therapy of prespecified redundant combinations of antimicrobials. Analysed at the ICU level.

Antimicrobial resistance rateEvaluated over calendar month periods during months 1-7 of the study

Number of multidrug-resistant pathogens (as specified by WHO priority list) / number of patients

Antimicrobial prescribing rateEvaluated over calendar month periods during months 1-7 of the study

Number of patients receiving at least 1 antimicrobial / number of patients admitted to ICU in the same period

© Copyright 2025. All Rights Reserved by MedPath